Vaccination for the prevention of herpes zoster with the attenuated live vaccine is currently not recommended for patients with rheumatic diseases while they are receiving biologic agents, but new evidence calls the validity of this guidance into question. Is it time to rethink the use of the herpes zoster vaccine in these patients?
References
Zhang, J. et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 308, 43–49 (2012).
Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 57, 1–30 (2008).
Smitten, A. L. et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 57, 1431–1438 (2007).
Strangfeld, A. et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with antiTNFα agents. JAMA 301, 737–744 (2009).
Edmunds, W. J. & Brisson, M. The effect of vaccination on the epidemiology of varicella zoster virus. J. Infect. 44, 211–219 (2002).
Oxman, M. N. et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352, 2271–2284 (2005).
Singh, J. A. et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. (Hoboken) 64, 625–639 (2012).
Zhang, J. et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res. Ther. 13, R174 (2011).
Sartori, A. M. A review of the varicella vaccine in immunocompromised individuals. Int. J. Infect. Dis. 8, 259–270 (2004).
Agarwal, N., Ollington, K., Kaneshiro, M., Frenck, R. & Melmed, G. Y. Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. Vaccine 30, 1413–1424 (2012).
Acknowledgements
The authors would like to thank E. Matteson for review of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Bongartz, T., Orenstein, R. Zoster vaccine and biologic agents: time to question a paradigm?. Nat Rev Rheumatol 8, 636–638 (2012). https://doi.org/10.1038/nrrheum.2012.168
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2012.168
- Springer Nature Limited